This framework predicts drug-drug interactions using pharmacophore-aware graphs and SMILES sequences, suggesting a new approach for medication safety.
Accurate prediction of potential drug-drug interactions (DDIs) is vital for ensuring medication safety and efficacy. Existing graph-based methods typically focus on molecular structures but often overlook the complementary semantic information embedded in SMILES (Simplified Molecular Input Line Entry System) representations. To address this gap, we propose CMCL-DDI, a Cross-view Mutual Contrastive Learning framework that jointly leverages pharmacophore-aware molecular graphs and SMILES sequences. Specifically, we encode pharmacophore-based subgraphs to capture functional molecular features and aggregate them into expressive graph-level embeddings. In parallel, SMILES sequences are encoded to preserve sequential drug characteristics. A contrastive learning strategy aligns both views in a shared latent space, facilitating mutual representation enhancement. Furthermore, we design a cross-attention fusion module to integrate heterogeneous features, enabling robust and interpretable DDI prediction. Extensive experiments on benchmark datasets demonstrate that CMCL-DDI consistently outperforms state-of-the-art models, highlighting the effectiveness of cross-view representation learning for DDI prediction. The source codes are available at https://github.com/95LY/CMCL-DDI .
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: